LINC00996: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC00996

NCBI ID: G285972

LINC00996

Other Name(s): long intergenic non-protein coding RNA 996 | Long intergenic non-protein coding RNA 996

LINC00996: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC00996 is a long non-coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located within the last exon of the human HSP70 gene, which encodes a protein involved in the detoxification of xenobiotics and other harmful substances. LINC00996 is unique among its kind, as it is not a protein but rather a non-protein coding RNA. This article will discuss the potential implications of LINC00996 as a drug target and biomarker.

Structure and Expression

LINC00996 is a 24.8 kilobase (kb) RNA molecule with 19 exons and 18 introns. It is expressed in most tissues and cells of the human body. The RNA is highly conserved across different species, with the exception of a single base change at position 22 between the 5' and 3' ends of the molecule.

function

LINC00996 is involved in the detoxification of xenobiotics and other harmful substances through its encoded protein, the heat shock protein 70 (HSP70). HSP70 is a protein that can interact with a variety of small molecules, including drugs, toxins, and other harmful substances. By doing so, HSP70 can either enhance the detoxification process or facilitate the formation of insoluble particles that can be eliminated from the body.

Drug Interaction with LINC00996

LINC00996 has the potential to serve as a drug target due to its unique mechanism of action. One of the most promising strategies to target LINC00996 is to inhibit its expression or function by introducing small molecules or antibodies that specifically target the RNA. This approach could be Useful for treating various diseases caused by the overproduction of HSP70, such as neurodegenerative disorders, autoimmune diseases, and Zhangqiu disease.

Biomarker Potential

LINC00996 has the potential to serve as a biomarker for various diseases caused by the overproduction of HSP70. One of the most promising applications of LINC00996 as a biomarker is its potential to diagnose neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These disorders are characterized by the progressive degeneration of brain cells and the loss of cognitive function. LINC00996 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and Parkinson's disease, and it has also been used as a potential therapeutic target in these disorders [4 ].

Another promising application of LINC00996 as a biomarker is its potential to diagnose various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, leading to inflammation and joint damage. LINC00996 has been shown to be involved in the regulation of immune responses and has been used as a potential therapeutic target in these diseases.

Conclusion

In conclusion, LINC00996 is a long non-coding RNA that has the potential to serve as a drug target and biomarker. Its unique mechanism of action and high conservation across different species make it an attractive target for small molecule and antibody-based therapies. Further research is needed to fully understand the role of LINC00996 in disease progression and to develop effective therapies based on its unique properties.

Protein Name: Long Intergenic Non-protein Coding RNA 996

The "LINC00996 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00996 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets